

CAROLINA FAMILY HEALTH CENTERS, INC. PROTOCOL

TITLE: PRC-111 Automatic Substitution of Oral Antidiabetic Agents

EFFECTIVE DATE: January 28, 2025

SECTION: Clinical Protocols

REFERENCE POLICY: N/A

RESPONSIBLE CHIEF OF STAFF: Chief Medical Officer

RESPONSIBLE COMMITTEE: Pharmacy & Therapeutics CIT

REVIEWED: 09/23/2025, 12/15/2025

I. PURPOSE

The purpose of this protocol is to define the parameters for automatic therapeutic drug substitution of oral antidiabetic products which are allowed in the pharmacies of Carolina Family Health Centers, Inc. (CFHC, Inc.).

II. PROTOCOL

The need for automatic therapeutic drug substitution may arise in a variety of circumstances including: product removal from the market, patient ineligibility for a bulk or medication assistance program, or when a prescriber writes for a non-formulary product. This protocol is not intended to outline or define generic/biosimilar substitution referenced in *PHR-300.04 Product Selection*.

For new and refill prescriptions for oral antidiabetic products originating from CFHC, Inc. prescribers, the pharmacy may automatically substitute when needed as described below.

Dipeptidyl Peptidyl Peptidase 4 (DDP-4) Inhibitors:

<u>Original Prescription</u>	<u>Substituted Prescription</u>
Januvia 25mg, 50mg, or 100mg total daily dose (TDD)	Tradjenta 5 mg QD
Janumet 50/500mg QD	Contact prescriber. Dose does not qualify for automatic substitution.
Janumet 50/500mg BID	Jentadueto 2.5/500mg BID
Janumet 50/1000mg QD	Jentadueto XR 5/1000mg QD
Janumet 50/1000mg BID	Jentadueto 2.5/1000mg BID
Janumet XR 50/500mg QD	Contact prescriber. Dose does not qualify for automatic substitution.
Janumet XR 50/500mg BID	Jentadueto XR 5/1000mg QD
Janumet XR 50/1000mg QD	Jentadueto XR 5/1000mg QD
Janumet XR 50/1000mg BID	Jentadueto XR 2.5/1000mg BID
Janumet XR 100/1000mg QD	Jentadueto XR 5/1000mg QD

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors:

<u>Original Prescriptions</u>	<u>Substituted Prescription</u>
Jardiance 10 mg & Metformin 1000 mg (TDD)	Synjardy 5/500 mg - 1 tablet BID OR Synjardy XR 10/1000 mg - 1 tablet QD
Jardiance 10 mg & Metformin 2000 mg (TDD)	Synjardy 5/1000 mg - 1 tablet BID OR Synjardy XR 5/1000 mg - 2 tablets QD
Jardiance 25 mg & Metformin 1000 mg (TDD)	Synjardy 12.5/500 mg - 1 tablet BID OR Synjardy XR 25/1000 mg - 1 tablet QD
Jardiance 25 mg & Metformin 2000 mg (TDD)	Synjardy 12.5/1000 mg - 1 tablet BID OR Synjardy XR 12.5/1000 mg - 2 tablets QD

<u>Original Prescriptions</u>	<u>Substituted Prescription</u>
Farxiga 5 mg & Metformin 500 mg (TDD)	Xigduo XR 5/500 mg - 1 tablet QD
Farxiga 5 mg & Metformin 1000 mg (TDD)	Xigduo XR 5/1000 mg - 1 tablet QD
Farxiga 5 mg & Metformin 2000 mg (TDD)	Xigduo XR 2.5/1000 mg - 2 tablets QD
Farxiga 10 mg & Metformin 500 mg (TDD)	Xigduo XR 10/500 mg - 1 tablet QD
Farxiga 10 mg & Metformin 1000 mg (TDD)	Xigduo XR 5/500 mg - 2 tablets QD OR Xigduo XR 10/1000 mg - 1 tablet QD
Farxiga 10 mg & Metformin 2000 mg (TDD)	Xigduo XR 5/1000 mg - 2 tablets QD


Per *PHR-300.18 A*

Per *PHR-300.18 Automatic Substitution*, pharmacists provide patient counseling on the switch. Additionally, pharmacy staff update the patient's electronic health record (EHR) with the substituted prescription information and route the encounter to the prescriber for notification. Prescribers have the right to override the automatic therapeutic drug substitution.

III. DEFINITION

- **Automatic therapeutic drug substitution:** the pharmacist-initiated substitution of one medication for a therapeutically equivalent [but different] medication without prior prescriber approval

This protocol shall remain in effect for all patients of Carolina Family Health Centers, Inc., effective 12/15/2025 until rescinded.


Abraham Chaparro, MD
Chief Medical Officer

12/19/25
Date